Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 3
2001 pubmed

Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.

Broglio. F F; Arvat. E E; Benso. A A; Gottero. C C; Muccioli. G G; Papotti. M M; van der Lely. A J AJ; Deghenghi. R R; Ghigo. E E

Key Findings

  • Ghrelin sharply increases GH, raises glucose, and suppresses insulin in humans.
  • Hexarelin also raises GH but does not affect glucose or insulin levels.
  • The metabolic impact of hexarelin appears milder than that of natural ghrelin despite similar GH‑releasing potency.

Practical Outcomes

  • For biohackers using GH secretagogues, hexarelin may be a safer option for acute GH spikes because it doesn't cause the rapid rise in blood sugar or drop in insulin that ghrelin does. This information can help refine dosing protocols to prioritize metabolic stability while still achieving GH elevation.

Summary

In a small study of healthy young adults, giving the natural hormone ghrelin caused a big jump in growth hormone, raised blood sugar, and lowered insulin. The synthetic GH secretagogue hexarelin also boosted growth hormone but did NOT change blood sugar or insulin levels. This suggests hexarelin can raise GH without the immediate metabolic side‑effects seen with ghrelin.

Abstract

Ghrelin, a 28 amino acid gastric hormone is a natural ligand of the GH Secretagogue (GHS) receptor (GHS-R) and strongly stimulates GH secretion though, like synthetic GHS, it shows other endocrine and non-endocrine activities. Aim of the present study was to clarify whether ghrelin administration influences insulin and glucose levels in humans. To this goal, we compared the effects of ghrelin, hexarelin, a synthetic GHS, or placebo on insulin and glucose as well as on GH levels in 11 normal young volunteers (age [mean +/- SEM]: 28.5 +/- 3.1 yr; BMI: 22.2 +/- 0.9 Kg/m(2)). Ghrelin induced very marked increase in GH secretion (DeltaAUC(0-180): 5777.1 +/- 812.6 microg/l/h; p < 0.01) which was not modified by placebo. Placebo administration did not modify insulin and glucose levels. On the other hand, ghrelin administration induced a prompt increase in glucose levels (DeltaAUC(0-180): 1343.1 +/- 443.5 mg/dl/h; p < 0.01 vs. saline). Absolute glucose levels at +15' were already higher than those at baseline (93.9 +/- 7.1 mg/dl; p < 0.01) and persisted elevated up to 165' (90.3 +/- 5.8 mg/dl; p < 0.01 vs. 0'). Ghrelin administration was also followed by a decrease in serum insulin levels (DeltaAUC(0-180): -207.1 +/- 70.5 mU/l/h; p < 0.05 vs. saline). Absolute insulin levels were significantly reduced from 30' (11.4 +/- 0.9 mU/l, p < 0.1 vs. 0'), showed the nadir at +45' (10.0 +/- 0.6 mU/l, p < 0.01 vs. 0') and then persisted lower (p < 0.01) than baseline up to +105'. Hexarelin administration did not modify glucose and insulin levels despite its marked GH-releasing effect (DeltaAUC(0-180): 4156.8 +/- 1180.3 microg/l/h; p < 0.01 vs. saline) that was slightly lower (p < 0.05) than that of ghrelin. In conclusion, these findings show that, besides stimulating GH secretion, ghrelin is a gastric hormone possessing metabolic actions such as hyperglycemic effect and lowering effect on insulin secretion in humans, at least after acute administration.

Study Information

Provider

pubmed

Year

2001

DOI

10.1210/jcem.86.10.8098